Disposition of 4456 shares by Guggenhime Andrew of Vaxcyte at 75.46 subject to Rule 16b-3
| PCVX Stock | USD 78.65 0.70 0.88% |
Slightly above 62% of Vaxcyte's investor base is looking to short. The analysis of the overall investor sentiment regarding Vaxcyte suggests that many traders are alarmed. Vaxcyte's investing sentiment can be driven by a variety of factors including economic data, Vaxcyte's earnings reports, geopolitical events, and overall market trends.
Vaxcyte |
Filed transaction by Vaxcyte Officer: President And Cfo. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at macroaxis.com
Vaxcyte Fundamental Analysis
We analyze Vaxcyte's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vaxcyte using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vaxcyte based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Owned By Insiders
Shares Owned By Insiders Comparative Analysis
Vaxcyte is currently under evaluation in shares owned by insiders category among its peers. Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
Vaxcyte Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Vaxcyte stock to make a market-neutral strategy. Peer analysis of Vaxcyte could also be used in its relative valuation, which is a method of valuing Vaxcyte by comparing valuation metrics with similar companies.
Peers
Vaxcyte Related Equities
| IMCR | Immunocore Holdings | 5.34 | ||||
| MRUS | Merus BV | 2.55 | ||||
| SNDX | Syndax Pharmaceuticals | 2.17 | ||||
| TVTX | Travere Therapeutics | 1.84 | ||||
| NUVL | Nuvalent | 1.52 | ||||
| VTYX | Ventyx Biosciences | 0.66 | ||||
| AKRO | Akero Therapeutics | 0.25 | ||||
| LQDA | Liquidia Technologies | 0.19 | ||||
| VRDN | Viridian Therapeutics | 0.06 | ||||
| TECH | Bio Techne | 0.11 | ||||
| LRMR | Larimar Therapeutics | 0.68 | ||||
| LEGN | Legend Biotech | 1.30 | ||||
| APLS | Apellis Pharmaceuticals | 2.12 | ||||
| STRO | Sutro Biopharma | 2.42 | ||||
| BMRN | Biomarin Pharmaceutical | 3.32 | ||||
| ACLX | Arcellx | 3.81 |
Additional Tools for Vaxcyte Stock Analysis
When running Vaxcyte's price analysis, check to measure Vaxcyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxcyte is operating at the current time. Most of Vaxcyte's value examination focuses on studying past and present price action to predict the probability of Vaxcyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxcyte's price. Additionally, you may evaluate how the addition of Vaxcyte to your portfolios can decrease your overall portfolio volatility.